BioCentury | Aug 9, 2019
Finance

Stem cells (re)generate rewards for Versant, Bayer

The combination of stem cells, gene therapy and regenerative medicine was not in vogue in 2016, but Versant and Bayer felt it had enough promise to make a bet on creating and funding BlueRock. Now...
BC Innovations | Dec 22, 2016
Finance

Starting up stem cells

In launching BlueRock Therapeutics with a $225 million series A round, comprehensive IP portfolio and set of strategic partnerships, Versant Ventures and Bayer AG are sending a message they are not only ready to go...
BC Innovations | Nov 4, 2016
Strategy

The next (re)generation

Regenerative medicine is continuing to draw believers from the scientific and investment communities, who are putting stock in the technology’s potential to create transformational therapies. But while there’s plenty of enthusiasm for the scientific progress,...
BC Extra | Mar 24, 2015
Company News

Management tracks

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) appointed Timothy Wright as EVP of business development, strategy and innovation, effective April 13. Wright was director of the Drug Discovery and Development Institute at The Ohio State University Comprehensive...
BC Week In Review | Jan 5, 2015
Company News

Tengion genitourinary, gene/cell therapy, transplant news

Regenerative medicine company Tengion filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. Tengion was developing Neo-Kidney Augment , a bioabsorbable scaffold seeded with renal cells cultured from the patient’s...
BC Extra | Dec 31, 2014
Company News

Tengion files for Chapter 7 bankruptcy

Regenerative medicine company Tengion Inc. (OTCQB:TNGN) filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. The filing triggered a default under the terms of two private placements of senior...
BC Week In Review | Sep 29, 2014
Company News

Tengion gene/cell therapy, transplant news

Regenerative medicine company Tengion hired Jefferies to explore strategic options. Tengion said the decision allows it to realize the value of its organ regeneration platform, but declined to comment further. At June 30, the company...
BC Week In Review | Jan 13, 2014
Company News

Spark Therapeutics management update

Spark Therapeutics LLC , Philadelphia, Pa.   Business: Gene/Cell therapy, Ophthalmic, Hematology   Hired: Carol Greve-Philips as SVP of business development and strategy, formerly VP of corporate development at Genzyme Corp. , which Sanofi acquired; and Joseph...
BC Week In Review | Aug 12, 2013
Company News

Tengion management update

Tengion Inc. (OTCQB:TNGN), Winston-Salem, N.C.   Business: Genitourinary, Gene/Cell therapy, Transplant   Promoted: Brian Davis to SVP of finance while remaining CFO  ...
BC Week In Review | Jul 15, 2013
Financial News

Tengion completes private placement of senior convertible notes

Tengion Inc. (OTCQB:TNGN), Winston-Salem, N.C.   Business: Genitourinary, Gene/Cell therapy, Transplant   Date completed: 7/1/13   Type: Private placement of senior convertible notes   Raised: $18.6 million   Placement agent: Roth Capital Partners   Shares...
Items per page:
1 - 10 of 86
BioCentury | Aug 9, 2019
Finance

Stem cells (re)generate rewards for Versant, Bayer

The combination of stem cells, gene therapy and regenerative medicine was not in vogue in 2016, but Versant and Bayer felt it had enough promise to make a bet on creating and funding BlueRock. Now...
BC Innovations | Dec 22, 2016
Finance

Starting up stem cells

In launching BlueRock Therapeutics with a $225 million series A round, comprehensive IP portfolio and set of strategic partnerships, Versant Ventures and Bayer AG are sending a message they are not only ready to go...
BC Innovations | Nov 4, 2016
Strategy

The next (re)generation

Regenerative medicine is continuing to draw believers from the scientific and investment communities, who are putting stock in the technology’s potential to create transformational therapies. But while there’s plenty of enthusiasm for the scientific progress,...
BC Extra | Mar 24, 2015
Company News

Management tracks

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) appointed Timothy Wright as EVP of business development, strategy and innovation, effective April 13. Wright was director of the Drug Discovery and Development Institute at The Ohio State University Comprehensive...
BC Week In Review | Jan 5, 2015
Company News

Tengion genitourinary, gene/cell therapy, transplant news

Regenerative medicine company Tengion filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. Tengion was developing Neo-Kidney Augment , a bioabsorbable scaffold seeded with renal cells cultured from the patient’s...
BC Extra | Dec 31, 2014
Company News

Tengion files for Chapter 7 bankruptcy

Regenerative medicine company Tengion Inc. (OTCQB:TNGN) filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. The filing triggered a default under the terms of two private placements of senior...
BC Week In Review | Sep 29, 2014
Company News

Tengion gene/cell therapy, transplant news

Regenerative medicine company Tengion hired Jefferies to explore strategic options. Tengion said the decision allows it to realize the value of its organ regeneration platform, but declined to comment further. At June 30, the company...
BC Week In Review | Jan 13, 2014
Company News

Spark Therapeutics management update

Spark Therapeutics LLC , Philadelphia, Pa.   Business: Gene/Cell therapy, Ophthalmic, Hematology   Hired: Carol Greve-Philips as SVP of business development and strategy, formerly VP of corporate development at Genzyme Corp. , which Sanofi acquired; and Joseph...
BC Week In Review | Aug 12, 2013
Company News

Tengion management update

Tengion Inc. (OTCQB:TNGN), Winston-Salem, N.C.   Business: Genitourinary, Gene/Cell therapy, Transplant   Promoted: Brian Davis to SVP of finance while remaining CFO  ...
BC Week In Review | Jul 15, 2013
Financial News

Tengion completes private placement of senior convertible notes

Tengion Inc. (OTCQB:TNGN), Winston-Salem, N.C.   Business: Genitourinary, Gene/Cell therapy, Transplant   Date completed: 7/1/13   Type: Private placement of senior convertible notes   Raised: $18.6 million   Placement agent: Roth Capital Partners   Shares...
Items per page:
1 - 10 of 86